CN115916768A - 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 - Google Patents

含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN115916768A
CN115916768A CN202180041057.4A CN202180041057A CN115916768A CN 115916768 A CN115916768 A CN 115916768A CN 202180041057 A CN202180041057 A CN 202180041057A CN 115916768 A CN115916768 A CN 115916768A
Authority
CN
China
Prior art keywords
compound
formula
tautomer
enantiomer
racemate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041057.4A
Other languages
English (en)
Inventor
杨方龙
贾敏强
陈刚
郭沛骅
张利敏
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN115916768A publication Critical patent/CN115916768A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

本公开涉及含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用。具体而言，本公开涉及一种通式(I)所示的含硫异吲哚啉类衍生物、其制备方法及含有该衍生物的药物组合物以及其作为治疗剂的用途，特别是作为Cereblon调节剂在治疗多发性骨髓瘤领域的用途。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN202180041057.4A 2020-07-20 2021-07-20 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 Pending CN115916768A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202010696995 2020-07-20
CN2020106969955 2020-07-20
CN2020107834832 2020-08-06
CN202010783483 2020-08-06
CN202011223930 2020-11-05
CN2020112239305 2020-11-05
CN202110410441 2021-04-16
CN2021104104419 2021-04-16
PCT/CN2021/107297 WO2022017365A1 (zh) 2020-07-20 2021-07-20 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN115916768A true CN115916768A (zh) 2023-04-04

Family

ID=79728998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041057.4A Pending CN115916768A (zh) 2020-07-20 2021-07-20 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用

Country Status (11)

Country Link
US (1) US20230257366A1 (zh)
EP (1) EP4183781A4 (zh)
JP (1) JP2023534528A (zh)
KR (1) KR20230042057A (zh)
CN (1) CN115916768A (zh)
AU (1) AU2021314401A1 (zh)
BR (1) BR112023000817A2 (zh)
CA (1) CA3184711A1 (zh)
MX (1) MX2023000868A (zh)
TW (1) TW202214594A (zh)
WO (1) WO2022017365A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023138647A1 (zh) * 2022-01-19 2023-07-27 江苏恒瑞医药股份有限公司 一种含硫异吲哚啉类衍生物的晶型
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679380A (zh) * 2007-03-20 2010-03-24 细胞基因公司 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法
CN102822165A (zh) * 2010-02-11 2012-12-12 细胞基因公司 芳基甲氧基异吲哚啉衍生物和包括其的组合物及它们的使用方法
WO2019014100A1 (en) * 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
BRPI0518282A2 (pt) 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
US11192898B2 (en) * 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
WO2019226770A1 (en) 2018-05-23 2019-11-28 Celgene Corporation Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
CN114085212B (zh) 2018-09-30 2023-05-02 中国科学院上海药物研究所 异吲哚啉类化合物、其制备方法、药物组合物及用途
JP2022548775A (ja) * 2019-09-19 2022-11-21 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン スピロ環式アンドロゲン受容体タンパク質分解剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679380A (zh) * 2007-03-20 2010-03-24 细胞基因公司 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法
CN102822165A (zh) * 2010-02-11 2012-12-12 细胞基因公司 芳基甲氧基异吲哚啉衍生物和包括其的组合物及它们的使用方法
WO2019014100A1 (en) * 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSHUA D. HANSEN 等: "Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma", 《J. MED. CHEM.》, 4 March 2020 (2020-03-04), pages 6648 - 6676 *

Also Published As

Publication number Publication date
KR20230042057A (ko) 2023-03-27
TW202214594A (zh) 2022-04-16
MX2023000868A (es) 2023-02-22
WO2022017365A1 (zh) 2022-01-27
US20230257366A1 (en) 2023-08-17
JP2023534528A (ja) 2023-08-09
CA3184711A1 (en) 2022-01-27
BR112023000817A2 (pt) 2023-02-07
EP4183781A4 (en) 2024-01-03
AU2021314401A1 (en) 2023-03-09
EP4183781A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
RU2605096C2 (ru) Пиразолохинолиновое производное
CN111032646B (zh) 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
CN107278203B (zh) 作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪
CN113801114B (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN115448923A (zh) 嘧啶并环化合物及其制备方法和应用
CN113544131A (zh) 吡咯并杂环类衍生物、其制备方法及其在医药上的应用
TW202039496A (zh) 做為腺苷受體拮抗劑之9-經取代胺基三唑喹唑啉衍生物、醫藥組合物及其用途
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
CN114805336A (zh) 稠合咪唑类化合物、其制备方法及其在医药上的应用
CN115916768A (zh) 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
CN111386275A (zh) 高活性sting蛋白激动剂
CN113980032A (zh) 稠合四环类衍生物、其制备方法及其在医药上的应用
CN114746414A (zh) 氮杂-喹啉化合物及其用途
CN114907377A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
JP2022543690A (ja) 架橋ヘテロシクリル置換ピリミジン化合物、その調製方法、及びその薬学的使用
CN116669736A (zh) 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
CN112996783B (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
CN115867552A (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN114456173B (zh) 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN114685429A (zh) 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用
CN115605479A (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202313592A (zh) 喹啉胺類化合物、其製備方法及其在醫藥上的應用
WO2022166810A1 (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
CN116693510A (zh) 二氢苯并呋喃类化合物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090714

Country of ref document: HK